From GlobeNewswire: 2025-06-20 13:00:00

GH Research PLC submitted a response to the FDA regarding the clinical hold on its Investigational New Drug Application for GH001. The company is committed to working with the agency to bring GH001 to patients. GH001 showed promising results in a Phase 2b trial for treatment-resistant depression. The company’s CEO, Dr. Velichka Valcheva, expressed optimism about the potential of GH001 to change the way TRD is treated. Forward-looking statements in the press release highlight the company’s future plans and expectations, while acknowledging the risks and uncertainties involved. Investors can contact Julie Ryan for more information.



Read more at GlobeNewswire: GH Research Submits Complete IND Hold Response to FDA Ahead